The TKTL1 (transketolase-like protein 1) antibody is a tool used to detect the expression of the TKTL1 protein, a member of the transketolase family involved in the pentose phosphate pathway (PPP). TKTL1 plays a critical role in cellular metabolism, particularly in cancer cells, where it is associated with enhanced aerobic glycolysis (Warburg effect) and NADPH production, supporting tumor growth under hypoxic conditions. Overexpression of TKTL1 has been linked to aggressive cancer progression, metastasis, and poor prognosis in various cancers, including colorectal, breast, and head-and-neck carcinomas.
TKTL1 antibodies are primarily utilized in research to investigate its metabolic contributions to oncogenesis and its potential as a diagnostic or therapeutic target. These antibodies enable the detection of TKTL1 in tissues or cell lines via techniques like immunohistochemistry, Western blotting, or ELISA. Notably, TKTL1’s homology with other transketolase family members (e.g., TKTL2) necessitates rigorous validation of antibody specificity to avoid cross-reactivity. Recent studies also explore TKTL1’s role in epigenetic regulation and drug resistance, expanding its relevance in precision oncology.
Despite its promise, challenges remain in standardizing TKTL1 detection across studies, partly due to variability in antibody performance and epitope recognition. Ongoing research aims to refine antibody-based assays and evaluate TKTL1 inhibition strategies, positioning it as a potential biomarker or target in cancer therapeutics.